Abecma sales disappoint again as BCMA competition ramps up, FDA adcomm looms

Fourth-quar­ter US sales of Bris­tol My­ers Squibb’s BC­MA-tar­get­ing CAR-T ther­a­py Abec­ma last year de­clined by 40% com­pared to the same pe­ri­od in 2022, pri­mar­i­ly due to com­pet­i­tive pres­sure.

Abec­ma pulled in $56 mil­lion in US rev­enue and $100 mil­lion to­tal world­wide, BMS re­port­ed in its earn­ings up­date Fri­day, fig­ures that rep­re­sent­ed 40% and 20% drops, re­spec­tive­ly. Com­pe­ti­tion from oth­er BC­MA-tar­get­ing drugs drove the de­cline, a com­pa­ny spokesper­son told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.